TD Cowen restated a buy rating on Editas Medicine, which also disclosed insider sales to the SEC.
1 report, 1 independent
Updated Aug 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen restated a buy rating on Editas Medicine, which also disclosed insider sales to the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Editas Medicine
discovery-phase pharmaceutical company
Nothing else this week.
-
TD Cowen
American investment bank
Related events
- TD Cowen reiterated its buy rating on ExlService Holdings, Inc. shares.
- TD Cowen restated a 'buy' rating on Affiliated Managers Group (AMG) on June 6, 2026.
- Financial firms Keefe, Bruyette & Woods and TD Cowen issued rating and price target updates, alongside company disclosures filed with the SEC.
- Datadog saw institutional investment changes tracked by the SEC and received a buy rating from TD Cowen.
- TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.